Cited by 462Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People

Open access

De Meyer, Geert·2010·Archives of Neurology

DOI 10.1001/archneurol.2010.179PMC PMC2963067

Open this paper in CoChat — free account

Abstract

OBJECTIVE: To identify biomarker patterns typical for Alzheimer disease (AD) in an independent, unsupervised way, without using information on the clinical diagnosis. DESIGN: Mixture modeling approach. SETTING: Alzheimer's Disease Neuroimaging Initiative database. PATIENTS OR OTHER PARTICIPANTS: Cognitively normal persons, patients with AD, and individuals with mild cognitive impairment. MAIN OUTCOME MEASURES: Cerebrospinal fluid-derived beta-amyloid protein 1-42, total tau protein, and phosphorylated tau(181P) protein concentrations were used as biomarkers on a clinically well-characterized data set. The outcome of the qualification analysis was validated on 2 additional data sets, 1 of which was autopsy confirmed. RESULTS: Using the US Alzheimer's Disease Neuroimaging Initiative data set, a cerebrospinal fluid beta-amyloid protein 1-42/phosphorylated tau(181P) biomarker mixture model identified 1 feature linked to AD, while the other matched the "healthy" status. The AD signature was found in 90%, 72%, and 36% of patients in the AD, mild cognitive impairment, and cognitively normal groups, respectively. The cognitively normal group with the AD signature was enriched in apolipoprotein E epsilon4 allele carriers. Results were validated on 2 other data sets. In 1 study consisting of 68 autopsy-confirmed AD cases, 64 of 68 patients (94% sensitivity) were correctly classified with the AD feature. In another data set with patients (n = 57) with mild cognitive impairment followed up for 5 years, the model showed a sensitivity of 100% in patients progressing to AD. CONCLUSIONS: The mixture modeling approach, totally independent of clinical AD diagnosis, correctly classified patients with AD. The unexpected presence of the AD signature in more than one-third of cognitively normal subjects suggests that AD pathology is active and detectable earlier than has heretofore been envisioned.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/archneurol.2010.179

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Elements of Statistical Learning
Hastie, T., Friedman, J., & Tibshirani, R. (2001) · Springer Series in Statistics · doi:10.1007/978-0-387-21606-5 · Cited by 24,162
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
ROCR: visualizing classifier performance in R
Sing, T., Sander, O., Beerenwinkel, N., & Lengauer, T. (2005) · Computer applications in the biosciences · doi:10.1093/bioinformatics/bti623 · Cited by 3,172
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048
-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease
Engler, H., Forsberg, A., Almkvist, O., Blomquist, G., Larsson, E., Savitcheva, I., Wall, A. E., Ringheim, A., Långström, B., & Nordberg, A. K. (2006) · Brain · doi:10.1093/brain/awl178 · Cited by 614

Show all 24 references

Sorted by citations

Items 201–300 of 455

Longitudinal Functional Brain Mapping in Supernormals
Wang, X., Ren, P., Baran, T. M., Raizada, R. D. S., Mapstone, M. E., Lin, F. V., & Initiative, T. A. D. N. (2017) · Cerebral Cortex · doi:10.1093/cercor/bhx322 · Cited by 34
Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer’s disease
Chatterjee, M., del Campo, M., Morrema, T. H. J., de Waal, M. W. J., van der Flier, W. M., Hoozemans, J. J. M., & Teunissen, C. E. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0383-x · Cited by 33
Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
ADNI, Duits, F. H., Wesenhagen, K. E. J., Ekblad, L. L., Wolters, E. E., Willemse, E. A. J., Scheltens, P., van der Flier, W. M., Teunissen, C. E., Visser, P. J., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00713-3 · Cited by 34
Biological markers of Alzheimer?s disease
de Souza, L. C., Sarazin, M., Teixeira, A. L., Caramelli, P., dos Santos, A. M., & Dubois, B. (2014) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20130233 · Cited by 33
Early microglial and astrocyte reactivity in preclinical Alzheimer's disease
Fernández‐Matarrubia, M., Barrero, A. V., Renuncio‐García, M., Aguilella, M., Lage, C., López‐García, S., Ocejo-Vinyals, J. G., Martínez‐Dubarbie, F., Molfetta, G. D., Pozueta‐Cantudo, A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70502 · Cited by 37
A Molecularly Imprinted Electrochemical Gas Sensor to Sense Butylated Hydroxytoluene in Air
Emam, S., Adedoyin, A. A., Geng, X., Zaeimbashi, M., Adams, J., Ekenseair, A. K., Podlaha, E. J., & Sun, N. X. (2018) · Journal of Sensors · doi:10.1155/2018/3437149 · Cited by 32
AD risk score for the early phases of disease based on unsupervised machine learning
Wang, Z., Tang, Z., Zhu, Y., Pettigrew, C. A., Soldan, A., Gross, A. L., & Albert, M. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12140 · Cited by 34
P50: A candidate ERP biomarker of prodromal Alzheimer׳s disease
Green, D. L., Payne, L., Robi Polikar, A., Moberg, P. J., Wolk, D. A., & Kounios, J. (2015) · Brain Research · doi:10.1016/j.brainres.2015.07.054 · Cited by 31
Biomarkers in Alzheimer’s Disease
Riverol, M., & López, O. L. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00046 · Cited by 33
The Mental Status Examination in Patients With Suspected Dementia
Grossman, M., & Irwin, D. J. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000298 · Cited by 32
The end of Alzheimer's disease—From biochemical pharmacology to ecopsychosociology: A personal perspective
Whitehouse, P. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.017 · Cited by 32
Structural evolution and membrane interactions of Alzheimer's amyloid‐beta peptide oligomers: New knowledge from single‐molecule fluorescence studies
Johnson, R. D., Steel, D. G., & Gafni, A. (2014) · Protein Science · doi:10.1002/pro.2479 · Cited by 29
Diagnosis of Alzheimer's disease in Brazil: Supplementary exams
Caramelli, P., Teixeira, A. L., Buchpiguel, C. A., Lee, H. W., LIVRAMENTO, J. A., Fernandez, L. L., & Anghinah, R. (2011) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642011dn05030004 · Cited by 30
Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database
Ito, K., Hutmacher, M. M., & Corrigan, B. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9271-3 · Cited by 29
Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia
Oh, E. S., Blennow, K., Bigelow, G. E., Inouye, S. K., Marcantonio, E. R., Neufeld, K. J., Rosenberg, P. B., Troncoso, J. C., Wang, N., Zetterberg, H., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204695 · Cited by 29
Persistent and Progressive Outer Retina Thinning in Frontotemporal Degeneration
Kim, B. J., Grossman, M., Song, D., Saludades, S., Pan, W., Dominguez, S., Dunaief, J. L., Alemán, T. S., Ying, G., & Irwin, D. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00298 · Cited by 31
Plasmonic 3D-structures based on silver decorated nanotips for biological sensing
Coluccio, M. L., Francardi, M., Gentile, F., Candeloro, P., Ferrara, L., Perozziello, G., & Fabrizio, E. M. D. (2015) · Optics and Lasers in Engineering · doi:10.1016/j.optlaseng.2015.04.020 · Cited by 28
Synergistic Interactions between Alzheimer’s Aβ40 and Aβ42 on the Surface of Primary Neurons Revealed by Single Molecule Microscopy
Chang, C.-C., Althaus, J. C., Carruthers, C. J. L., Sutton, M. A., Steel, D. G., & Gafni, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082139 · Cited by 28
Ultrasensitive SERS nanoprobe-based multiplexed digital sensing platform for the simultaneous quantification of Alzheimer's disease biomarkers
Shim, J.-E., Kim, Y. J., Hahm, E., Choe, J., Baek, A., Kim, R. M., & You, E. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117216 · Cited by 29
Investigational medications for treatment of patients with Alzheimer disease.
Potter, P. E. (2010) · PubMed · Cited by 27
Using CSF biomarkers to replicate genetic associations in Alzheimer's disease
Schott, J. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.008 · Cited by 27
Amyloid-beta accumulation, neurogenesis, behavior, and the age of rats.
Church, R. M., Miller, M. C., Freestone, D. M., Chiu, C., Osgood, D. P., Machan, J. T., Messier, A. A., Johanson, C. E., & Silverberg, G. D. (2014) · Behavioral Neuroscience · doi:10.1037/a0036433 · Cited by 26
Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis
Paciotti, S., Sepe, F. N., Eusebi, P., Farotti, L., Cataldi, S., Gatticchi, L., & Parnetti, L. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.03.1612 · Cited by 26
The discriminative capacity of CSF β-amyloid 42 and Tau in neurodegenerative diseases in the Chinese population
Ye, L., Li, X., Zhang, Y.-B., Cheng, H.-R., Ma, Y., Chen, D.-F., Tao, Q., Li, H., & Wu, Z. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116756 · Cited by 25
CALHM1 P86L Polymorphism Modulates CSF Aβ Levels in Cognitively Healthy Individuals at Risk for Alzheimer’s Disease
Koppel, J. L., Campagne, F., Vingtdeux, V., Dreses‐Werringloer, U., Ewers, M., Rujescu, D., Hampel, H. J., Gordon, M. L., Christen, E., Chapuis, J., et al. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00154 · Cited by 25
Pyroglutamate-Modified Amyloid-β(3–42) Shows α-Helical Intermediates before Amyloid Formation
Dammers, C., Reiß, K., Gremer, L., Lecher, J., Ziehm, T., Stoldt, M., Schwarten, M., & Willbold, D. (2017) · Biophysical Journal · doi:10.1016/j.bpj.2017.03.007 · Cited by 25
Memory Alteration Test to Detect Amnestic Mild Cognitive Impairment and Early Alzheimer’s Dementia in Population with Low Educational Level
Custodio, N., Lira, D., Herrera‐Pérez, E., Montesinos, R., Castro‐Suárez, S., Cuenca, J., & Valeriano-Lorenzo, L. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00278 · Cited by 25
Identify a shared neural circuit linking multiple neuropsychiatric symptoms with Alzheimer’s pathology
Initiative, A. T. A. D. N., Wang, X., Ren, P., Mapstone, M. E., Conwell, Y., Porsteinsson, A. P., Foxe, J. J., Raizada, R. D. S., & Lin, F. V. (2017) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9767-y · Cited by 25
Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform
Martínez‐Dubarbie, F., Guerra-Ruiz, A. R., López‐García, S., Lage, C., Fernández‐Matarrubia, M., Nevado-Cáceres, Á., Rivera‐Sánchez, M., Barrero, A. V., Pozueta‐Cantudo, A., García‐Martínez, M., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01719-5 · Cited by 26
Identifying Key MicroRNA Signatures for Neurodegenerative Diseases With Machine Learning Methods
Li, Z., Guo, W., Ding, S., Chen, L., Feng, K., Huang, T., & Cai, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.880997 · Cited by 23
Cerebrospinal fluid biomarkers of Alzheimer’s disease in cognitively healthy elderly
Glodzik, L. (2013) · Frontiers in bioscience · doi:10.2741/4170 · Cited by 25
A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers
Spies, P. E., Claassen, J. A. H. R., Peer, P. G. M., Blankenstein, M. A., Teunissen, C. E., Scheltens, P., van der Flier, W. M., Rikkert, M. G. M. O., & Verbeek, M. M. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.01.010 · Cited by 23
Dementia screening, biomarkers and protein misfolding
Galvin, J. E. (2011) · Prion · doi:10.4161/pri.5.1.14439 · Cited by 23
Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians
Rosa‐Neto, P., Hsiung, G. R., Masellis, M., & participants, O. B. O. T. C. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt223 · Cited by 24
A Two-Study Comparison of Clinical and MRI Markers of Transition from Mild Cognitive Impairment to Alzheimer’s Disease
Devanand, D. P., Liu, X., Brown, P. J., Huey, E. D., Stern, Y., & Pelton, G. H. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/483469 · Cited by 23
The clinical application of optimized AT(N) classification in Alzheimer’s clinical syndrome (ACS) and non-ACS conditions
Kasuga, K., Tsukie, T., Kikuchi, M., Tokutake, T., Washiyama, K., Shimizu, S., Yoshizawa, H., Kuroha, Y., Yajima, R., Mori, H., et al. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.03.007 · Cited by 22
How many biomarkers to discriminate neurodegenerative dementia?
Sancesario, G. M., & Bernardini, S. (2015) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2015.1051658 · Cited by 23
Difficult Diagnoses: Family Caregivers’ Experiences During and Following the Diagnostic Process for Dementia
Gibson, A., & Anderson, K. A. (2011) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317511400306 · Cited by 22
Advances in our Understanding of the Pathophysiology, Detection and Management of Cerebral Amyloid Angiopathy
Pontes‐Neto, O. M., Auriel, E., & Greenberg, S. M. (2012) · European Neurological Review · doi:10.17925/enr.2012.07.02.134 · Cited by 22
Functional brain network centrality is related to APOE genotype in cognitively normal elderly
Wink, A. M., Tijms, B. M., ten Kate, M., Raspor, E., de Munck, J. C., Altena, E., Ecay‐Torres, M., Clerigué, M., Estanga, A., García‐Sebastián, M., et al. (2018) · Brain and Behavior · doi:10.1002/brb3.1080 · Cited by 24
Comparative Analysis of Different Definitions of Amyloid-β Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer
Milà‐Alomà, M., Salvadó, G., Shekari, M., Grau‐Rivera, O., Sala‐Vila, A., Sánchez‐Benavides, G., Arenaza‐Urquijo, E. M., Gónzalez‐de‐Echávarri, J. M., Simon, M., Kollmorgen, G., et al. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2020.51 · Cited by 22
Higher education is not associated with greater cortical thickness in brain areas related to literacy or intelligence in normal aging or mild cognitive impairment
Pillai, J. A., McEvoy, L. K., Hagler, D. J., Holland, D., Dale, A. M., Salmon, D. P., Galasko, D., & Fennema‐Notestine, C. (2012) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2012.702733 · Cited by 23
Predicting brain activity using a Bayesian spatial model
Derado, G., Bowman, F. D., Zhang, L., & Initiative, A. T. A. D. N. (2012) · Statistical Methods in Medical Research · doi:10.1177/0962280212448972 · Cited by 21
Impact of Amyloid Burden on Regional Functional Synchronization in the Cognitively Normal Older Adults
Kang, D. W., Choi, W. H., Jung, W. S., Um, Y. H., Lee, C. U., & Lim, H. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-15001-8 · Cited by 21
Influence of Physiological Variables and Comorbidities on Plasma Aβ40, Aβ42, and p-tau181 Levels in Cognitively Unimpaired Individuals
Martínez‐Dubarbie, F., Guerra-Ruiz, A. R., López‐García, S., Irure‐Ventura, J., Lage, C., Fernández‐Matarrubia, M., Pozueta‐Cantudo, A., García‐Martínez, M., Corrales‐Pardo, A., Bravo, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031481 · Cited by 20
The Impact of Cerebrospinal Fluid Biomarkers on the Diagnosis of Alzheimer’s Disease
Engelborghs, S., & Bastard, N. L. (2012) · Molecular Diagnosis & Therapy · doi:10.1007/bf03262201 · Cited by 20
Clinical indications for analysis of Alzheimer's disease CSF biomarkers
Engelborghs, S. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.024 · Cited by 20
Preclinical Characterization of a Novel Class of18F-Labeled PET Tracers for Amyloid-β
Brockschnieder, D., Schmitt‐Willich, H., Heinrich, T. K., Varrone, A., Gulyás, B. Z., Tóth, M., Andersson, J. D., Boemer, U., Krause, S., Friebe, M., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.104810 · Cited by 20
Cognitive and brain cytokine profile of non-demented individuals with cerebral amyloid-beta deposition
Aguilar, L. F., Iulita, M. F., Orciani, C., Tanna, N., Yang, J., Bennett, D. A., & Cuello, A. C. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02169-0 · Cited by 20
Functional Magnetic Resonance Imaging in Aging and Dementia: Detection of Age-Related Cognitive Changes and Prediction of Cognitive Decline
Woodard, J. L., & Sugarman, M. A. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_159 · Cited by 20
Evidence of Syntaxin 1A Involvement in Migraine Susceptibility
Lemos, C., Pereira-Monteiro, J. M., Mendonça, D. M., Ramos, E. M., Barros, J., Sequeiros, J., Alonso, I. D. C. M. P., & Sousa, A. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.37 · Cited by 20
Elevated plasma neurofilament light was associated with multi-modal neuroimaging features in Alzheimer’s disease signature regions and predicted future tau deposition
Hu, Q., Shi, M., Li, Y., & Zhao, X. (2024) · BMC Neurology · doi:10.1186/s12883-024-03728-7 · Cited by 19
Several Direct and Calculated Biomarkers from the Amyloid-β Pool in Blood are Associated with an Increased Likelihood of Suffering from Mild Cognitive Impairment
Pérez‐Grijalba, V., Pesini, P., Monleón, I., Boada, M., Tárraga, L., Ruiz, A., Martínez‐Lage, P., José, I. S., & Sarasa, M. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121744 · Cited by 20
Using cognitive decline in novel trial designs for primary prevention and early disease-modifying therapy trials of Alzheimer's disease
Darby, D., Brodtmann, A. G., Woodward, M., Budge, M. M., & Maruff, P. T. (2011) · International Psychogeriatrics · doi:10.1017/s1041610211000354 · Cited by 19
Finding a pathological diagnosis for A lzheimer's disease: Are inflammatory molecules the answer?
Bhamra, M. S., & Ashton, N. J. (2012) · Electrophoresis · doi:10.1002/elps.201200161 · Cited by 21
Longitudinal trajectory of plasma p-tau217 in cognitively unimpaired subjects
Martínez‐Dubarbie, F., Guerra-Ruiz, A. R., López‐García, S., Lage, C., Fernández‐Matarrubia, M., Pozueta‐Cantudo, A., García‐Martínez, M., Corrales‐Pardo, A., Bravo, M., López‐Hoyos, M., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01642-1 · Cited by 18
Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform
Martínez‐Dubarbie, F., Guerra-Ruiz, A. R., López‐García, S., Lage, C., Fernández‐Matarrubia, M., Infante, J., Pozueta‐Cantudo, A., García‐Martínez, M., Corrales‐Pardo, A., Bravo, M., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.152 · Cited by 18
Aβ1-17 is a Major Amyloid-β Fragment Isoform in Cerebrospinal Fluid and Blood with Possible Diagnostic Value in Alzheimer's Disease
Pérez‐Grijalba, V., Pesini, P., Allué, J. A., Sarasa, L., Montañés, M., Lacosta, A.-M., Casabona, D., José, I. S., Boada, M., Tárraga, L., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140156 · Cited by 20
Driving and dementia: a clinician's guide
Wilson, S., & Pinner, G. (2013) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.111.009555 · Cited by 19
Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies
Kang, J., Ryoo, N., Shin, D. W., Trojanowski, J. Q., & Shaw, L. M. J. (2014) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2014.18.6.447 · Cited by 18
Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap
Frisoni, G. B., Perani, D., Bastianello, S., Bernardi, G., Porteri, C., Boccardi, M., Cappa, S. F., Trabucchi, M., & Padovani, A. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.033 · Cited by 18
A model for improving the treatment and care of Alzheimer's disease patients through interdisciplinary research
Trojanowski, J. Q., Arnold, S. E., Karlawish, J. H., Naylor, M. D., Brunden, K. R., & Lee, V. M. ‐. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.08.005 · Cited by 19
Alzheimer's disease severity, objectively determined and measured
Gross, A. L., Mungas, D., Leoutsakos, J., Albert, M., Jones, R. N., & Initiative, A. D. N. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.08.005 · Cited by 19
It Is Time to Study Overlapping Molecular and Circuit Pathophysiologies in Alzheimer’s and Lewy Body Disease Spectra
Wakasugi, N., & Hanakawa, T. (2021) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2021.777706 · Cited by 17
Longitudinal Effects of Metabolic Syndrome on Alzheimer and Vascular Related Brain Pathology
Lin, F. V., Lo, R. Y., Cole, D., Ducharme, S., Chen, D., Mapstone, M. E., Porsteinsson, A. P., & Initiative, A. D. N. (2014) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000363285 · Cited by 17
Diagnostic value of cerebro-spinal fluid biomarkers in dementia with lewy bodies
Bousiges, O., & Blanc, F. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.11.027 · Cited by 18
History in perspective: How Alzheimer's Disease came to be where it is?
Ahmed, T. F., Ahmed, A., & Imtiaz, F. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147342 · Cited by 21
Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer’s Disease
Coart, E., Barrado, L. G., Duits, F. H., Scheltens, P., van der Flier, W. M., Teunissen, C. E., van der Vies, S. M., Burzykowski, T., & Initiative, A. D. N. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142886 · Cited by 17
The Use of Cerebrospinal Fluid and Neuropathologic Studies in Neuropsychiatry Practice and Research
Kansal, K., & Irwin, D. J. (2015) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.02.002 · Cited by 18
Systems medicine and the integration of bioinformatic tools for the diagnosis of alzheimer's disease
Orešič, M., Lötjönen, J. M. P., & Soininen, H. S. (2010) · Genome Medicine · doi:10.1186/gm204 · Cited by 17
Exploring the association between mild behavioral impairment and plasma p‐tau217: Implications for early detection of Alzheimer's disease
Ghahremani, M., Leon, R., Smith, E. E., & Ismail, Z. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70119 · Cited by 16
Deriving reference values for nerve conduction studies from existing data using mixture model clustering
Reijntjes, R. H. A. M., Potters, W. V., Kerkhof, F. I., van Zwet, E. W., van Rossum, I. A., Verhamme, C., & Tannemaat, M. R. (2021) · Clinical Neurophysiology · doi:10.1016/j.clinph.2021.04.013 · Cited by 16
Three-Dimensional Structure of Proteins and Disorders of Protein Misfolding
Bhagavan, N. V., & Ha, C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-416687-5.00004-x · Cited by 16
Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF‐AD study
Smith, R. G., Pishva, E., Kouhsar, M. P., Imm, J. L., Dobričić, V., Johannsen, P., Wittig, M., Franke, A., Vandenberghe, R. R., Schaeverbeke, J. M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14098 · Cited by 15
Biomarkers of primary open-angle glaucoma
Knepper, P. A., Samples, J. R., & Yue, B. Y. (2010) · Expert Review of Ophthalmology · doi:10.1586/eop.10.73 · Cited by 15
CSF cutoffs for MCI due to AD depend on APOEε4 carrier status
Marizzoni, M., Ferrari, C., Babiloni, C., Albani, D., Barkhof, F., Cavaliere, L., Didic, M., Forloni, G., Fusco, F., Galluzzi, S., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.12.019 · Cited by 15
Biomarcadores en la enfermedad de Alzheimer
Ribas, G. G., López-Sendón, J. L., & Caldentey, J. G. (2014) · Revista de Neurología · doi:10.33588/rn.5807.2013394 · Cited by 14
Scoping review: Health needs of the family caregivers of elderly stroke survivors
Felix, M. S., Le, T. N. P., Wei, M., & Puspitasari, D. C. (2021) · Health & Social Care in the Community · doi:10.1111/hsc.13371 · Cited by 14
Initial Memory Deficit Profiles in Patients with a Cerebrospinal Fluid Alzheimer's Disease Signature
Xie, J., Gabelle, A., Dorey, A., Garnier‐Crussard, A., Perret‐Liaudet, A., Delphin‐Combe, F., Bathsavanis, A., Dauphinot, V., Lehmann, S., Mercier, B., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131916 · Cited by 15
Alzheimer’s Disease Dietary Supplements in Websites
Palmour, N., Vanderbyl, B. L., Zimmerman, E., Gauthier, S. G., & Racine, É. (2013) · HEC Forum · doi:10.1007/s10730-013-9217-1 · Cited by 13
Supporting self-management in early dementia: a contribution towards ‘living well’?
Cheffey, J., Hill, L., Roberts, G. A., & Marlow, R. (2013) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.112.011023 · Cited by 12
Cognitive function in very old men does not correlate to biomarkers of Alzheimer’s disease
Veličkaitė, V., Giedraitis, V., Ström, K., Alafuzoff, I. I., Zetterberg, H., Lannfelt, L., Kilander, L., Larsson, E., & Ingelsson, M. (2017) · BMC Geriatrics · doi:10.1186/s12877-017-0601-6 · Cited by 12
Anterior Cingulate Structure and Perfusion is Associated with Cerebrospinal Fluid Tau among Cognitively Normal Older Adult APOE ɛ 4 Carriers
Hays, C. C., Zlatar, Z. Z., Meloy, M. J., Osuna, J., Liu, T. T., Galasko, D. R., & Wierenga, C. E. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190504 · Cited by 12
Multi-Parametric Classification of Vascular Cognitive Impairment and Dementia: The Impact of Diverse Cerebrovascular Injury Biomarkers
Lang, B., Kindy, M. S., Kozel, F. A., Schultz, S. K., & Taheri, S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170733 · Cited by 11
Age-related hearing loss is not linked to cerebrospinal fluid levels of β-amyloid or p-tau181
Martínez‐Dubarbie, F., Lobo, D., Rollán‐Martínez‐Herrera, M., López‐García, S., Lage, C., Fernández‐Matarrubia, M., Pozueta‐Cantudo, A., García‐Martínez, M., Corrales‐Pardo, A., Bravo, M., et al. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07143-7 · Cited by 10
Near‐Infrared Fluorescent Probe for the Early Diagnosis of Alzheimer's Disease
Liu, Y., Sun, Y., Zhao, P., Liu, Z., Wang, Y., Wang, Y., Zhao, R., Wang, C., & Wang, S. (2025) · Medicinal Research Reviews · doi:10.1002/med.70000 · Cited by 12
Enhancing Alzheimer Disease Detection Using Neuropsychiatric Symptoms: The Role of Mild Behavioural Impairment in the Revised NIA-AA Research Framework
Leon, R., Ghahremani, M., Guan, D. X., Smith, E. E., Zetterberg, H., & Ismail, Z. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251366634 · Cited by 11
Progressive Memory Circuit Impairments along with Alzheimer’s Disease Neuropathology Spread: Evidence from in vivo Neuroimaging
Li, K., Wang, S., Luo, X., Zeng, Q., Jiaerken, Y., Xu, X., Wang, C., Liu, X., Li, Z., Zhao, S., et al. (2020) · Cerebral Cortex · doi:10.1093/cercor/bhaa162 · Cited by 10
O espectro clínico e laboratorial da doença de Alzheimer
Moreira, M. A., & Moreira, S. V. (2020) · Revista Psicologia em Pesquisa · doi:10.34019/1982-1247.2020.v14.30649 · Cited by 11
Effect of embryonic cerebrospinal fluid on proliferation and differentiation of neuroprogenitor cells.
Yari, S., Parivar, K., Nabiuni, M., & Keramatipour, M. (2013) · Europe PMC (PubMed Central) · Cited by 10
Searching for Novel Biomarkers Using High Resolution Diffusion Tensor Imaging
Yassa, M. A. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-0005 · Cited by 10
Understanding Cognitive Screening Tools: Navigating Uncertainty in Everyday Clinical Practice
Swallow, J. (2016) · Palgrave Macmillan UK eBooks · doi:10.1057/978-1-137-54097-3_7 · Cited by 10
TRPV4 mRNA is elevated in the caudate nucleus with NPH but not in Alzheimer’s disease
White, H., Webb, R., McKnight, I., Legg, K., Lee, C., Lee, P. H. U., Spicer, O. S., & Shim, J. W. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.936151 · Cited by 10
Prevalence Estimates for Latent Neurodegenerative Disease
Montine, T. J. (2010) · Toxicologic Pathology · doi:10.1177/0192623310391481 · Cited by 10
Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis
Michaud, T. L., Initiative, A. D. N., Kane, R. L., McCarten, J. R., Gaugler, J. E., Nyman, J. A., & Kuntz, K. M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150066 · Cited by 10
In Vitro Effects of Wistar Rat Prenatal and Postnatal Cerebrospinal Fluid on Neural Differentiation and P roliferation of Mesenchymal Stromal Cells Derived from Bone Marrow.
Shokohi, R., Nabiuni, M., Irian, S., & Miyan, J. A. (2018) · PubMed Central · doi:10.22074/cellj.2018.4130 · Cited by 10
Dementia
Filley, C. M., & Anderson, C. A. (2011) · Neurology · doi:10.1212/wnl.0b013e31820c35e1 · Cited by 9
Frontal Network Syndrome Testing
Hoffmann, M. W. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317513488920 · Cited by 9
Electroencephalogram Signal Analysis in Alzheimer's Disease Early Detection
Rodrigues, P. M., Freitas, D., Teixeira, J. P., Alves, D., & Garrett, C. (2017) · International Journal of Reliable and Quality E-Healthcare · doi:10.4018/ijrqeh.2018010104 · Cited by 9
The Global Impact of Alzheimer’s Disease
Carrillo, M. C., Thies, W. H., & Bain, L. J. (2012) · Advances in biological psychiatry · doi:10.1159/000335374 · Cited by 9

Authors: De Meyer, G.
Venue: Archives of Neurology
Publisher: American Medical Association (AMA)
Published: 2010-08-01
Volume: 67
Issue: 8
Pages: 949
ISSN: 0003-9942 (ISSN-L)
DOI: 10.1001/archneurol.2010.179
PMC: PMC2963067
OpenAlex: W2141854336
Cited by: 462
References: 24
Citations by year: 2026: 4 · 2025: 14 · 2024: 14 · 2023: 8 · 2022: 13 · 2021: 18 · 2020: 43 · 2019: 16 · 2018: 19 · 2017: 24 · 2016: 15 · 2015: 31 · 2014: 44 · 2013: 35 · 2012: 58
FWCI: 42.86
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Archives of Neurology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
UCL Discovery (University College London) (submittedVersion)
Lund University Publications (Lund University) (submittedVersion)
VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders: National Institutes of Health (5u01ag024904-10)
National Institute on Aging (U01-AG-024904, P30AG010124, U19AG010483)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords: Alzheimer's disease, biomarker signatures, cerebrospinal fluid, amyloid-beta 42, phosphorylated tau, total tau, mixture models, cognitively normal elderly, mild cognitive impairment, APOE ε4, unsupervised classification
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Cognition, Female, Follow-Up Studies, Humans, Male, Peptide Fragments, ROC Curve, Reproducibility of Results, Biomarkers, Geriatric Assessment, Amyloid beta-Peptides, tau Proteins, Apolipoprotein E4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks